Researcher resensitize solid tumors to cell death


Manchester – Hypoxia occurs in most solid tumours and is known to suppress chemotherapy-induced cell death (apoptosis). Researchers from Manchester University have shown that human colorectal and small cell lung cancer cells can be resensitized to apoptosis under hypoxic conditions by a small molecule drug developed by Abbott (J Clin Invest. doi:10.1172/JCI43505). According to the team headed by Caroline Dive, cells in hypoxic regions of human tumours xenografted in mice were susceptible to ABT-737–induced apoptotic cell death. As ABT-737 synergized with conventional chemotherapeutic agents in tumour-bearing mice, the authors suggest that such a combination of drugs could improve treatment of
solid tumours. ABT737 mimics the BCL2 homology domain 3 (BH3) of BAD, a proapoptitic member of the Bcl2 protein family, while eliminating the antiapoptotic proteins Bcl-2, Bcl-X_L and Bcl-w. In hypoxic tumour cell cultures induction of apoptosis by ABT737 was dependent on Mcl-1 down regulation



London - Nothing is well if the end is not well. For Astra Zeneca the end of 2011 isn't well at all. A new anti-ovarian cancer drug and a planned antidepressant have underperformed in tests. As a result, AstraZeneca will take a...



Surrey – The UK government is investing an additional £80m (€93.5m) to fund continued development of the Institute for Animal Health (IAH) at Pirbright, an institute of the Biotechnology and Biological Sciences Research Council...



Rijeka/London – Allergies like asthma or psoriasis might arise from environmental toxins, suggest researchers from Rijeka University (Croatia) and King’s College (London). In mice, they identified a special population of T cells...



London – Interesting times ahead in the European cancer treatment market. A report states that in the UK alone, diagnosis and treatment costs are likely to increase by 62%, from £9.4 billion in 2010 to £15.3 billion by 2021. The...



York - Tissue Regenix Group plc plans to raise €29m through the sale of 181.8 million shares. The regenerative medical device company is held within the IP Group portfolio and a spin-out company from the University of Leeds. The...



London – Cancer Research UK has begun recruiting patients in the first phase of its Stratified Medicine Programme, which is aimed at finding cancer biomarkers and establishing a genetic testing service in the UK. The charity’s...



London – British Prime Minister David Cameron is trying to come to the rescue of Britain’s embattled biopharmaceutical industry. He has earmarked €210m to support a “biomedical catalyst fund” to back early-stage academic and...



London - David Cameron plans to come to the rescue of Britain's embattled biopharmaceutical industry. The conservative prime minister has earmarked £180m (€210 million) to support a "biomedical catalyst fund" to back ...



Cancer Research UK has started recruiting patients in the first phase of its Stratified Medicine Program, which is seeking to find cancer biomarkers and establish a genetic testing service in the U.K. The charity's multi-million...

Displaying results 11 to 20 out of 396

< Previous 11-20 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Current issue

All issues